

(19)



(11)

**EP 3 927 337 B8**

(12)

**CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:

**Corrected version no 1 (W1 B1)**  
**Corrections, see**  
**Bibliography INID code(s) 73**

(48) Corrigendum issued on:

**20.03.2024 Bulletin 2024/12**

(45) Date of publication and mention of the grant of the patent:

**14.02.2024 Bulletin 2024/07**

(21) Application number: **20710059.5**

(22) Date of filing: **24.02.2020**

(51) International Patent Classification (IPC):

**A61K 31/4045<sup>(2006.01)</sup> A61P 25/24<sup>(2006.01)</sup>**

(52) Cooperative Patent Classification (CPC):

**A61K 31/4045; A61P 25/24**

(86) International application number:

**PCT/EP2020/054803**

(87) International publication number:

**WO 2020/169850 (27.08.2020 Gazette 2020/35)**

(54) **5-METHOXY-N,N-DIMETHYLTRYPTAMINE (5-MEO-DMT) FOR TREATING MAJOR DEPRESSION**

5-METHOXY-N,N-DIMETHYLTRYPTAMINE (5-MEO-DMT) ZUR BEHANDLUNG VON SCHWEREN DEPRESSION

5-METHOXY-N,N-DIMETHYLTRYPTAMINE (5-MEO-DMT) POUR LE TRAITEMENT DE LA DEPRESSION MAJEURE

(84) Designated Contracting States:

**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR**

Designated Extension States:

**BA ME**

Designated Validation States:

**KH MA MD TN**

(30) Priority: **22.02.2019 EP 19158774**

(43) Date of publication of application:

**29.12.2021 Bulletin 2021/52**

(60) Divisional application:

**24157388.0**

**24157425.0**

(73) Proprietor: **GH Research Ireland Limited**

**D02 RY95 Dublin 2 (IE)**

(72) Inventor: **TERWEY, Theis**

**10119 Berlin (DE)**

(74) Representative: **Breuer, Markus et al**

**Sendlinger Straße 29  
80331 München (DE)**

(56) References cited:

**WO-A1-2018/195455 WO-A1-2019/081764**

- **UTHAUG MALIN V ET AL: "Prospective examination of synthetic 5-methoxy-N,N-dimethyltryptamine inhalation: effects on salivary IL-6, cortisol levels, affect, and non-judgment", PSYCHOPHARMACOLOGY, SPRINGER VERLAG, BERLIN, DE, vol. 237, no. 3, 10 December 2019 (2019-12-10), pages 773-785, XP037030419, ISSN: 0033-3158, DOI: 10.1007/S00213-019-05414-W [retrieved on 2019-12-10]**
- **OSÓRIO FDE L ET AL: "Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report", REVISTA BRASILEIRA DE PSIQUIATRIA, PUBL. SOLUTIONS, BR, vol. 37, no. 1, 1 January 2015 (2015-01-01), pages 13-20, XP009520464, ISSN: 1516-4446, DOI: 10.1590/1516-4446-2014-1496**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**EP 3 927 337 B8**

- THOMAS G ET AL: "Ayahuasca-assisted therapy for addiction: results from a preliminary observational study in Canada", CURRENT DRUG ABUSE REVIEWSE, BENTHAM SCIENCE PUBLISHERS LTD, vol. 6, no. 1, 1 March 2013 (2013-03-01), pages 30-42, XP009520465, ISSN: 1874-4737, DOI: 10.2174/15733998113099990003
- GEYER M A ET AL: "Behavioural and pharmacological studies of pharmahuasca in rodents", EUROPEAN NEUROPSYCHOPHARMACOLOGY, vol. 26, 2016, XP029787110, ISSN: 0924-977X, DOI: 10.1016/S0924-977X(16)30889-6
- CARHART-HARRIS R L ET AL: "Psilocybin with psychological support for treatment-resistant depression: six-month follow-up", PSYCHOPHARMACOLOGY, SPRINGER VERLAG, BERLIN, DE, vol. 235, no. 2, 8 November 2017 (2017-11-08), pages 399-408, XP036477494, ISSN: 0033-3158, DOI: 10.1007/S00213-017-4771-X [retrieved on 2017-11-08]
- SHEN HONG-WU ET AL: "Nonlinear Pharmacokinetics of 5-Methoxy-N,N-dimethyltryptamine in Mice", DRUG METABOLISM AND DISPOSITION, PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, US, vol. 39, no. 7 30 June 2011 (2011-06-30), pages 1227-1234, XP009520579, ISSN: 0090-9556, DOI: 10.1124/DMD.111.039107 Retrieved from the Internet: URL:<http://dmd.aspetjournals.org/cgi/doi/10.1124/dmd.111.039107>
- ALAN K. DAVIS ET AL: "5-methoxy- N,N -dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety", AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE, vol. 45, no. 2, 1 March 2019 (2019-03-01), pages 161-169, XP055695498, US ISSN: 0095-2990, DOI: 10.1080/00952990.2018.1545024